What I Tell My Clients About Coming Off Ozempic Without Regaining the Weight
I have a growing number of clients walking through my door with the same story.
They went on a GLP-1 — semaglutide, tirzepatide, sometimes compounded versions from telehealth clinics. They lost the weight. The food noise stopped. For the first time in years, maybe ever, eating felt simple. They felt in control. They got compliments. Their clothes fit. Their inflammatory markers improved. Their fasting glucose normalised.
And then, for one of a hundred reasons, they decided to stop.
The cost stopped making sense at $400–$600 a month indefinitely. The side effects became unsustainable — the persistent nausea, the gastroparesis, the wrecked relationship with food. They worried about long-term unknowns of a drug class that's only been used at population scale for a few years. They reached their goal weight and their prescriber agreed to taper them off. They got pregnant or wanted to. They lost their muscle mass and their bone density and looked in the mirror and didn't like what they saw underneath the smaller body.
Whatever the reason, they stopped. And almost all of them — without an intentional protocol — started regaining within weeks.
This isn't a moral failure. It isn't lack of discipline. It's predictable physiology that the prescribing conversation has not caught up with. And it's a problem that is about to land in functional health practices everywhere as the first big wave of GLP-1 users come off their drugs over the next 18–24 months.
I want to walk through what's actually happening in the body when you stop, why the standard advice ("just keep eating well and exercise") fails most people, and what an integrated post-GLP-1 protocol actually looks like from a functional medicine perspective.
What the data actually says about stopping
The published trial data on what happens after stopping GLP-1 receptor agonists is unambiguous. The STEP-1 trial extension followed semaglutide users after they discontinued the drug. Within 12 months, participants regained two-thirds of the weight they'd lost and reverted close to baseline on most cardiometabolic improvements. The SURMOUNT trials on tirzepatide show similar trajectories.
What the trials don't capture as well — but what shows up in clinical practice every day — is the accompanying psychological collapse. People who'd finally found peace with food describe the return of "food noise" as more distressing than the weight regain itself. The drug had silenced the constant background chatter about the next meal, the snack drawer, the leftover takeaway. When that silence ends, the experience is jarring in a way that's hard to explain to anyone who hasn't lived it.
The biology behind both the physical regain and the mental noise return is straightforward. GLP-1 receptor agonists work by binding GLP-1 receptors at supra-physiological hormone levels, 24 hours a day, seven days a week, for as long as you keep injecting. They mimic and amplify a satiety signalling pathway your body has always had. They don't, however, teach your body to make more of its own GLP-1. If anything, your endogenous GLP-1 response becomes blunter from disuse — like a muscle that atrophies when it doesn't need to fire.
When the drug clears (semaglutide's half-life is approximately one week, so by 4–6 weeks it's effectively gone), three things happen simultaneously:
The exogenous satiety signal disappears entirely. Your endogenous satiety signal is weaker than it was when you started. And your hypothalamic set point — the weight your brain considers "home" — is still pinned to your highest sustained pre-drug weight, fighting actively to return there.
This is the trap, and it's a physiological one. No amount of willpower changes the underlying signalling.
The muscle loss problem nobody talks about loudly enough
Before we get to what to do, I want to address what is probably the single most under-discussed issue in the GLP-1 conversation: muscle loss.
A 2024 meta-analysis estimated that 25–40% of total weight lost on GLP-1 receptor agonists is lean mass. That's not "some" muscle loss. That is catastrophic muscle and bone density loss across the board.
Why does this matter so much for the rebound?
Because muscle is your metabolic engine. A pound of muscle burns roughly 6 calories per day at rest. A pound of fat burns about 2. If you lost 30 pounds total on the drug and 10 of those were muscle, your daily resting energy expenditure dropped by about 60 calories every day, forever, compared to a hypothetical version of you that lost the same weight while protecting muscle.
Now compound that. Your appetite hormones bounce back to baseline (or worse) the moment you stop. Your daily calorie needs have dropped. The same eating patterns that maintained your post-drug weight are now in surplus. The rebound is essentially mathematically inevitable unless you do something about it.
This is the part that most prescribers don't communicate clearly, and most patients don't understand until they're three months off the drug and watching the scale climb.
The correction is straightforward but non-negotiable: protein intake high enough to protect muscle (1.6–2.2g per kg of body weight per day, every day, no exceptions), and resistance training that actually challenges the muscle (compound movements 3–4 times per week). I'll come back to this because it's foundational.
What an integrated post-GLP-1 protocol actually looks like
When a client comes to me either tapering off or recently off a GLP-1, I'm thinking about four things that need to happen simultaneously:
Reactivate endogenous satiety signalling so the body's own GLP-1, CCK, and PYY response can carry the work the drug was doing
Protect and rebuild muscle to defend metabolic rate
Restore metabolic flexibility so the body can efficiently switch between burning carbohydrates and burning fat
Address the psychological and behavioural shifts — food noise, decision fatigue, and the sleep and stress regulation that compound everything else
No single intervention does all four. The protocol is the bridge.
One: Reactivating endogenous satiety signalling
Your gut has its own satiety hormone system that pre-dates pharmaceuticals by all of human evolution. GLP-1, CCK (cholecystokinin), and PYY (peptide YY) are released by enteroendocrine cells lining your small intestine in response to specific food signals. They tell your brain you've eaten enough. They slow gastric emptying. They modulate insulin response. They are the system the drugs were piggybacking on.
The challenge after months on a GLP-1 receptor agonist is that this system has been functionally idle. The signalling pathway is intact, but it needs a reliable trigger to fire on, and most modern food doesn't provide one. Ultra-processed food bypasses bitter taste receptors almost entirely. Sugar-sweetened drinks blunt satiety responses. Constant grazing means the signalling never gets a clean run at the meal it's meant to regulate.
There's a category of botanicals that activate TAS2R bitter taste receptors in the small intestine, which in turn trigger the body's own GLP-1 cascade. The most clinically validated of these is Amarasate®, a patented bitter hops extract developed over 14 years at the New Zealand Institute for Plant and Food Research. Three published human clinical trials show it triggers a six-fold elevation of GLP-1 and CCK above baseline within an hour, reduces hunger by 30%, reduces cravings by 40%, and reduces calorie intake by 18%.
I use it as a structured satiety trigger for clients in the post-GLP-1 phase, dosed an hour before the meals where they're most vulnerable to overshooting. (For most people that's dinner and the post-dinner snacking window.) It's not a replacement for the drug — the magnitude of effect is much smaller — but it provides a repeatable, predictable trigger that lets the endogenous satiety system find its rhythm again.
It's available as Calocurb in capsule form, both internationally and through my own store. The dosing protocol matters: start low for the first two days to let the gut adjust to the elevated GLP-1 release, build up gradually over the first week, and time it to the meals that are hardest for you. Most clients find they don't need it before every meal — just the high-risk ones.
Two: Protecting and rebuilding muscle
This is the foundation. Everything else is decoration if you skip this.
The non-negotiables:
Protein intake of 1.6–2.2 grams per kilogram of body weight per day, every day. For a 70kg person that's 112–154g of protein daily. Most people coming off GLP-1s are eating less than half of this and don't realise it, because the drug suppressed their appetite for everything including the protein-rich meals they actually need.
Resistance training three to four times per week, prioritising compound movements. Squat patterns, hinge patterns, push, pull. If you've never lifted weights, this is the moment to start, ideally with a coach who can teach you form. Cardio is fine but cardio without resistance training accelerates muscle loss further and works against you in the post-drug phase.
Creatine monohydrate, 5g daily. The most-studied supplement in human history, with a robust evidence base for muscle retention, strength, and increasingly for cognitive function. It is one of the very few supplements I recommend to essentially every client over 40, and especially to anyone in a recovery phase from any kind of weight loss intervention.
Sleep, because muscle protein synthesis happens overnight. Six hours is not enough. Seven to nine hours, prioritised like medication, is the foundation that makes everything else work.
This is the part people skim and the part that determines whether the protocol succeeds or fails. There is no supplement, no peptide, no functional medicine intervention that compensates for inadequate protein and inadequate resistance training in the post-GLP-1 phase. The pharmacology can be brilliant; if the muscle isn't protected, the rebound is coming.
Three: Restoring metabolic flexibility
Months on a GLP-1 typically means months of significantly suppressed food intake, often with poor macro distribution because appetite suppression makes it hard to prioritise protein. The metabolic consequence is reduced flexibility — the body's ability to efficiently switch between burning carbohydrates and burning fat.
In a metabolically flexible person, dropping food intake triggers a smooth shift to fat oxidation. In a metabolically inflexible person, the same drop triggers fatigue, brain fog, cravings, and a stress response that drives cortisol and insulin in ways that promote fat storage.
The interventions that rebuild this:
Time-restricted eating, but introduced gradually. Don't try to drop into a 16:8 fast in the first month off the drug — your appetite system is already destabilised and you'll trigger a binge response. Start with a 12-hour overnight fast, work toward 14 hours over two to three weeks, then 16 hours if it suits you.
Walking after meals. Ten to fifteen minutes of light walking within 30 minutes of eating dramatically improves post-meal blood glucose response, which over time supports insulin sensitivity and metabolic flexibility. This is one of the highest-leverage interventions in all of metabolic health and it costs nothing.
Mitochondrial support. Your mitochondria do the actual fat-burning work at the cellular level. If they're sluggish — from age, from chronic inflammation, from the metabolic stress of months of caloric restriction — fat oxidation is sluggish. The supportive nutrients that show up consistently in this work are CoQ10, magnesium, the B vitamins (especially B1, B2, B3), bioavailable copper for the electron transport chain, and the NAD+ precursors NMN or NR. None of these are magic; all of them are foundational.
Cold exposure if your nervous system can tolerate it. A short cold shower or plunge two to three times per week meaningfully upregulates brown adipose tissue activity, which is the body's most metabolically active fat type.
Four: The behavioural and psychological piece
The food noise returning is the part nobody warns you about and the part that derails more post-GLP-1 clients than any other factor. Months of mental quiet around food, then a sudden return of intrusive thoughts about the next meal, the snacks in the cupboard, the leftover pizza in the fridge.
What helps:
Removing trigger foods from the home environment for the first 90 days off the drug. This is not weakness. It's intelligent design. Willpower is a finite resource, decision fatigue is real, and the post-drug period is exactly the wrong time to test it.
Protein-first eating, particularly in the morning. Thirty grams or more of protein within 30 minutes of waking blunts ghrelin response for the rest of the day and stabilises the hunger signal that food noise rides on.
Stress regulation as non-negotiable infrastructure. Cortisol drives both visceral fat accumulation and craving intensity. The post-GLP-1 phase is high-stress for most people simply because their body is recalibrating. This is where adaptogenic support like ashwagandha can play a meaningful role, where breathwork practice matters, where regular nervous system downregulation is genuinely medicinal.
Sleep, again, because everything cascades from it. A single night of bad sleep raises ghrelin and lowers leptin enough to override most of the supplements and protocols above. If sleep is broken, fix sleep first. Other tools won't compensate.
A realistic timeline
The first two weeks off the drug are a grace period. Hunger and cravings start returning but the drug hasn't fully cleared. Most people feel relatively in control and underestimate what's coming.
Weeks three to six are the real test. The drug is fully out of your system, your endogenous GLP-1 is sluggish, and the food noise is back at full volume. This is when most people who haven't built the bridge protocol begin to regain. Clients who've prepared for this window — protein dialled in, resistance training routine established, satiety support in place, trigger foods out of the house — get through it. Clients who haven't, regain.
Months two and three are where the new baseline establishes. If the weight has held in this window, the long-term odds shift dramatically in your favour.
Months four through twelve are the long game. Continue everything. The goal is to make the supports become identity-level habits — "I'm someone who lifts three times a week and eats protein with every meal" — rather than temporary scaffolding that gets dismantled the moment things feel stable.
Who needs this protocol and who doesn't
This is for the people coming off a GLP-1 drug who want to keep the weight off long-term and are willing to do the work on muscle, food environment, and behavioural infrastructure. It's a meaningful piece of work and it requires commitment.
It's not a replacement protocol for people who genuinely benefit from staying on a GLP-1 long-term under medical supervision. If your prescriber wants you on it for type 2 diabetes management, severe metabolic dysfunction, or other clinical indications, this article isn't telling you to stop. It's telling you what to do if and when you do.
And it's not a magic bridge that closes the gap completely. The drugs suppressed appetite by 70% or more. Calocurb suppresses by 30%. The bridge protocol is about closing the gap intelligently with multiple tools layered together — not pretending the gap doesn't exist or that one intervention does what the drug class did.
Where this is heading
The GLP-1 drug class is one of the most significant pharmacological developments in obesity medicine in 50 years. It's also being prescribed at a scale and pace that has outpaced our collective understanding of what happens at the population level when people stop. A whole cohort is about to find out — many of them without a strategy, many of them blaming themselves when the weight returns.
Functional medicine has a meaningful role to play here. Not as anti-pharmaceutical ideology, but as the clinical discipline that thinks in systems and bridges. The people I work with through my practice who have integrated the bridge protocol — pharmacological taper, satiety reactivation, muscle protection, metabolic flexibility, behavioural infrastructure — are the ones who keep the wins.
The system is gettable. The science is well-mapped. It just needs to be talked about more honestly than the prescribing conversation has been so far.
Lisa Tamati is a functional health practitioner, longevity researcher, and host of the Pushing The Limits podcast. She works with clients one-on-one through her practice on complex metabolic, longevity, and recovery cases. To enquire about working with Lisa, visit shop.lisatamati.com/collections/consultations.
If you'd like to learn more about Calocurb and the natural GLP-1 activation pathway, including the full breakdown comparing it to semaglutide, tirzepatide, retatrutide and liraglutide, listen to the dedicated Pushing The Limits episode here.
